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Cardiovascular disease in patients with end-stage renal disease (ESRD) is driven by a different set of processes than in the general
population. These processes lead to pathological changes in cardiac structure and function that include the development of left
ventricular hypertrophy and left ventricular dilatation and the development of myocardial fibrosis. Reduction in left ventricular
hypertrophy has been the established goal of many interventional trials in patients with chronic kidney disease, but a recent
systematic review has questionedwhether reduction of left ventricular hypertrophy improves cardiovascularmortality as previously
thought. The development of novel imaging biomarkers that link to cardiovascular outcomes and that are specific to the disease
processes in ESRD is therefore required. Postmortem studies of patients with ESRD on hemodialysis have shown that the extent of
myocardial fibrosis is strongly linked to cardiovascular death and accurate imaging of myocardial fibrosis would be an attractive
target as an imaging biomarker. In this article we will discuss the current imaging methods available to measure myocardial fibrosis
in patients with ESRD, the reliability of the techniques, specific challenges and important limitations in patients with ESRD, and
how to further develop the techniques we have so they are sufficiently robust for use in future clinical trials.
1. Introduction
Patients with end-stage renal disease (ESRD) are at signif-
icantly increased risk of cardiovascular death compared to
age-matched peers [1].TheUSRenalData System reports that
“cardiac death, cause unknown” and arrhythmia account for
25% of all deaths amongst hemodialysis (HD) patients, at an
event rate of 90–200/1000 patient years [2]. These excessive
rates of cardiovascular disease (CVD) are unexplained by
traditional risk factors [3] and strategies to improve CVD
related outcomes, such as coronary artery revascularization,
do not improve outcomes for patients on HD [4]. The
pathophysiological processes that drive CVD in patients with
ESRD are different to those that drive classical atherosclerotic
CVD and include chronic inflammation, increased arterial
stiffness, autonomic instability, and sympathetic overactivity.
These factors lead to the development of changes in cardiac
structure and function including left ventricular hypertrophy
(LVH), left ventricular (LV) dilatation, diffuse myocardial
fibrosis (DMF), and replacement fibrosis (myocardial scar-
ring) [5]. In healthy subjects the extracellular matrix (ECM)
makes up around 6% of the normal heart and is composed
of hydrated collagen and elastin fibrils produced by cardiac
fibroblasts [6]. Its physiological roles include determining
tissue mechanics, acting as an anchor for myocytes and as a
reservoir for growth factors. In disease states, the volume of
ECM can be increased more than 5-fold [7]. A postmortem
study of patients with chronic kidney disease (CKD), without
coronary artery disease, showed that >90% had myocardial
fibrosis (MF) and expanded ECM compartments on histo-
logical analysis. Furthermore, levels of MF were more severe
in patients on dialysis, progressed over time to replacement
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fibrosis, and partially regressed in patients who received renal
transplantation [8]. This study also suggested that extent and
severity of MF were the strongest predictor of death for
patients with renal failure.
It has been shown in a number of diseases that increased
amounts of MF correlate strongly with the development
of arrhythmias and heart failure and sudden cardiac death
(SCD) [9–12]; it is likely that this is also the case for patients
with renal disease [13]. Additionally MF contributes to
diastolic and systolic dysfunction through net accumulation
of ECM proteins in the cardiac interstitium that lead to
the following: increased LV stiffness; impaired LV diastolic
filling; ventricular arrhythmias; and SCD [12, 14, 15]. Three
types of MF have been described:
(1) Reactive interstitial fibrosis is commonly described
in patients with hypertension and diabetes mellitus
as a result of activation of the B-adrenergic sys-
tem and renin-angiotensin-aldosterone system. Stim-
ulated myofibroblasts increase collagen production
and deposition in the ECM. It is also present in
conditions such as dilated cardiomyopathy and states
of pressure overload such as aortic stenosis [16].
(2) Infiltrative interstitial fibrosis is less common and
characterized by deposition of insoluble substances
such as protein tangles in amyloidosis or glycosphin-
golipids in patients with Fabry’s disease.
(3) Replacement fibrosis is scarring that occurs after car-
diomyocyte damage or once myocardial cell integrity
has been affected. The fibrosis may be localised in
conditions such as ischemic cardiomyopathy (post-
myocardial infarction) affecting a particular coronary
territory or a more diffuse distribution of fibrosis as
seen in patients with dilated cardiomyopathy [17].
The development ofMF in patients with ESRD is complex
[18]. Arterial hypertension plays an important role in the
pathogenesis of MF in patients with ESRD but is not the
only driver. Patients with hypertensive heart disease without
CKD develop LVH, diastolic dysfunction and interstitial
and perivascular MF related to hemodynamic and humoral
factors [14, 19]. In early stage CKD hypertension remains the
driving force behind the development ofMF, but its influence
(whilst still important) reduces as CKD stages progress to
ESRD [20]. The importance of the unique environments of
CKD and ESRDmust not be underplayed in the pathogenesis
ofMF as the prevalence of LVH and diastolic dysfunction and
levels of MF are significantly higher in hypertensive patients
with CKD than in hypertensive patients without CKD [21–
23]. Arterial stiffness, activation of renin-angiotensin aldos-
terone system, intravascular volume expansion, oxidative
stress, systemic inflammation, and anaemia all contribute to
myocardial cell hypertrophy and LV remodelling in patients
with CKD and ESRD in addition to arterial hypertension.
Pathophysiological responses to these changes lead to acti-
vation of pathways that increase production of collagen
within the ECM leading to intermyocardial cell fibrosis
[24].
The development of DMF and its progression to replace-
ment (scar) fibrosis occur as a continuum. Whilst replace-
ment scar is irreversible, DMF is reversible as it occurs earlier
in the disease process. Imaging techniques that allow safe,
reliable, early detection of MF may improve disease risk
stratification, be an important imaging biomarker in clinical
research studies, and allow early treatment to prevent/slow
progression to replacement fibrosis or even reverse it.
Some strategies that have targeted LVH reduction in
dialysis patients have been shown to reduce SCD and CV
morbidity and mortality [25]. There is evidence in animal
models, humans, and even HD patients that regression of
LVH is accompanied by reductions in MF [26–29]. Given
the central association between fibrosis, LVH, morbidity, and
mortality in HD patients, being able to reliably measure MF
is crucial to understanding its potential as both a research
and clinical end point. The purpose of this review is to assess
the reliability of the imaging techniques currently available to
noninvasively assess MF and DMF in ESRD patients.
Imaging and Myocardial Fibrosis in Patients with ESRD.
Identification ofMF is historically donewith endomyocardial
biopsy. Endomyocardial biopsy is prone not only to sam-
pling error but also to significant morbidity and mortality
associated with the procedure itself [30, 31]. We will review
noninvasivemeasures of fibrosis using echocardiography and
cardiac magnetic resonance (CMR) imaging. Whilst some
of these techniques characterize and quantify myocardial
tissue directly, others use quantitative measures of cardiac
function as surrogates of MF. We will not discuss positron
emission tomography-computed tomography, as whilst it
could theoretically be used to measure MF in patients with
ESRD, the technique is yet to be studied in this population.
Contrast enhanced cardiac CTmay theoretically also be used
to evaluate MF in patients with ESRD, but it has never been
used for this purpose in this cohort. Cardiac CT has been
used to define MF in patients with hypertrophic cardiomy-
opathy who are unable to undergo CMR scanning due to
having implantable cardiac defibrillators [32] and does seem
to be able to define areas of MF in a similar way to certain
CMR techniques [33]. However, the technique requires the
use of iodinated contrast agents which may affect residual
renal function through contrast induced nephropathy [34]
and delivers a dose of ionizing radiation. It is for these reasons
that its use as a screening tool is not widespread in any
population and has never been and is unlikely to ever be used
in patients with ESRD.
2. Echocardiography
2.1. Speckle Tracking Echocardiography. When imaged by
ultrasound, natural acoustic reflections or “speckles” are
identified in myocardial tissue (Figure 1). These speckle
patterns are unique to the characteristics of each region of
myocardium. On imaging, a relatively stable speckle pattern
can be identified and defined as a fingerprint in order to track
this pattern in the next image frame throughout the cardiac
cycle. The speckle pattern can be tracked in two- or three-
dimensional images to identify deformation, independent
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Figure 1: Peak systolic strain assessment using speckle tracking echocardiography. (a) Two-chamber left ventricular strain. (b)Three-chamber
left ventricular strain assessment. (c) Four-chamber left ventricular strain. (d) Global and regional strain assessments generated from 2-
chamber, 3-chamber, and 4-chamber views.
of tethering and translational motion of the whole heart.
Speckle tracking echocardiography (STE) was developed in
the early 1990s [35] and the use of strain and strain rate
imaging has been validated against a number of standards
including sonomicrometry [36], tissue Doppler strain mea-
surements [37], and magnetic resonance imaging [38]. Strain
describes myocardial deformation and is usually expressed
as a percentage change from original point of measurement.
During the cardiac cycle, strain represents the lengthening
and shortening of the myocardial wall during diastole and
systole, respectively. Strain rate imaging represents the rate
at which deformation occurs expressed per second. Speckle
analysis allows examination of several planes in a single data
set (i.e., longitudinal, radial, and circumferential) to define
“myocardial strain” [39]. The average longitudinal or cir-
cumferential component of strain in the entire myocardium
is referred to as global longitudinal strain (GLS) or global
circumferential strain (GCS).
The theory behind the relationship between strain, strain
rate, and fibrosis is that fibrosis causes hypokinesia of the
tissue in affected regions thereby reducing the amount of
myocardial wall deformation which results in reduced (less
negative) strain values [40], a theory supported by animal
studies. Postmortem animal studies by Park et al. demon-
strated that radial and longitudinal early diastolic strain rates
postmyocardial infarction were significantly related to the
extent of interstitial fibrosismeasured by the cells-to-collagen
ratio (𝑟 = 0.88 and 0.81, resp.; 𝑝 < 0.01) [41].
Key studies that have used STE in patients with ESRD
are shown in Table 1 [42–44]. Kramann et al. induced kidney
disease in rats and found that LV strain (peak global radial
and circumferential) assessed by STE was significantly asso-
ciated with myocardial fibrosis on histological examination
of rats with kidney disease in comparison to control with
correlation coefficients of 0.701 and 0.678, respectively [42].
They extrapolated this information and measured strain in
human patients with ESRD and found significantly reduced
peak GLS values in ESRD patients in comparison to control
(−12.04 ± 3.54 versus −18.37 ± 4.29; 𝑝 < 0.0001). Pirat et al.
used STE to compare the strain values of patients on HD,
renal transplant recipients, and control subjects matched
for age and sex, excluding patients with clinical coronary
artery disease. All groups had similar ejection fractions, but
average GLS was, again, significantly reduced in HD patients
compared to renal transplant recipients, who similarly had
impairedGLS in comparison to control subjects (−10.2± 1.6%
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Table 1: Speckle tracking echocardiography used to assessmyocardial fibrosis in patientswith ESRD: STE, speckle tracking echocardiography;
HD, haemodialysis; PCC, Pearson’s correlation coefficient; LV, left ventricular; HR, hazard ratio.
Study Patient characteristics Results Limitations
Kramann et al. [42]
Animal study: 2 rat models with
induced kidney disease;
clinical study: 171 HD human patients
In rats, peak global radial and
circumferential strain was reduced and
correlated with interstitial fibrosis
(PCC of 0.701 and 0.678, resp.) on
histological examination
In ESRD patients, mean (±standard
deviation) global longitudinal peak
systolic was significantly reduced in
comparison to healthy subjects (−12.04
± 3.54 versus −18.37 ± 4.29, resp.;
𝑝 < 0.0001) and this had significant
effect on cardiovascular mortality HR
= 1.17 (CI: 1.04–1.30; 𝑝 < 0.006)
LV contractility may differ
in rats and humans;
therefore one cannot
entirely extrapolate animal
data to dialysis patients
Pirat et al. [43]
Cross-sectional study of 33 patients on
HD, 24 renal transplant recipients with
functional grafts, 26 age- and
sex-matched control subjects
Mean (±standard deviation) global
longitudinal systolic strain from the
4-chamber view was highest in control
subjects (−14.5% ± 2.9%) and was
higher in renal transplant recipients
(−12.5% ± 3.0%) than ESRD patients
(−10.2% ± 1.6%; 𝑝 ≤ 0.001)
demonstrating that myocardial
function, quantified by strain imaging,
is improved in renal transplant
recipients compared with ESRD
patients
Cross-sectional data study
therefore unable to
determine what happens to
patients with ESRD after
transplant
Chen et al. [44]
Case-control study with 35 HD
patients, 30 uremic nondialysis
patients, 32 healthy volunteers
LV longitudinal, radial, and global
strain values were significantly lower
in the nondialysis patients compared
with the other two groups (all
𝑝 < 0.001), indicating that reduced
strain improves upon starting dialysis.
3D strain and regional longitudinal
strain were reduced in HD patients
compared to controls (𝑝 < 0.01)
The nondialysis group had
a significantly lower
haemoglobin level than the
HD and control group. This
could be a confounding
factor
versus −12.5 ± 3.0% versus −14.5 ± 2.9%, resp.; 𝑝 < 0.001)
[43]. They also found that average systolic strain rate was
similar between controls (−0.76 ± 0.17 per sec) and renal
transplant recipients (−0.77 ± 0.21 per sec) and lower in HD
patients (−0.62 ± 0.13 per sec; 𝑝 < 0.001) [43]. Chen et al.
showed that, despite having normal LV ejection fractions,
global three-dimensional strain and regional longitudinal,
radial, and circumferential strain were all reduced in the
patients with uremia (HD and nondialysis) compared to age,
sex, heart rate, and blood pressure-matched controls. They
speculated that hypertension, LVH, LV remodelling, and MF
all contributed to LV dysfunction in uremic patients with
preserved LVEF [44]. These studies suggest GLS may be
a subclinical marker of cardiac dysfunction and a way of
assessing MF in patients with ESRD, although none of these
studies have been validated histologically.
Several studies have looked at STE strain analysis in
patients with advanced CKD (not on dialysis) compared to
matched HD patients [44–46]. These studies all suggested
that strain indices are reduced in patients with advanced
CKD compared to matched HD patients. The improvement
seen on commencement of HD is almost certainly to do
with the improvements in fluid balance and correction of
uremia and restoration of acid-base balance that accompany
commencement of HD. Levels of MF are known to be greater
in HD patients compared to patients with CKD [8, 47], and
the observation that strain improves at commencement of
HD suggests that measurement of MF with STE in patients
with renal failure has many potential confounding factors,
including cardiac loading.
A study by Leischik et al. assessed the observer vari-
ability of radial, circumferential, and longitudinal strain in
21 healthy controls [48]. Longitudinal strain had the best
intraobserver variability (9 ± 13.6% mean deviation, rho =
0.624, and𝑝 = 0.003), followed by circumferential strain (13.3
± 8.3%, rho = 0.406, and𝑝 = 0.068) and lowest in radial strain
(26.3 ± 30.1%, rho = 0.391, and 𝑝 = 0.080). Interobserver
analyses of longitudinal strain showed best reproducibility
(11.9 ± 9.5%, rho = 0.513, and 𝑝 = 0.017), followed by circum-
ferential strain (15.2 ± 12.0%, rho = 0.263, and 𝑝 = 0.249)
and the least consistent measurements in radial strain (35.9 ±
46.3%, rho = 0.382, and 𝑝 = 0.088). The use of radial strain
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Figure 2: Calibrated integrated backscatter analysis using echocar-
diography. Region of interest 1 (yellow square) is blood pool within
the left ventricle (mean echo-time 0.01 dB). Region of interest 2 (blue
square) is the pericardium (mean echo-time 33.96 dB). Region of
interest 3 (red square) is myocardium on the posterior wall (mean
echo-time 10.29 dB).
should be discouraged due to its poor observer variability. It
must also be noted that this study was conducted in healthy
control subjects, and the reproducibility of these measures
in ESRD patients is likely to be higher, especially given the
variability in volume status.
Gayat et al. assessed the agreement of 3D-STE between
different vendor software applications in patients with nor-
mal LV-systolic function. They found that intertechnique
agreement between measures of radial, longitudinal, and
circumferential strain was poor with intraclass correlation
coefficient < 0.4 [49]. This discordance must, therefore, be
taken into account when interpreting 3D deformation data.
It should be noted that strain and strain rate can be easily
measured with CMR, with superior reproducibility [50], and
GCS and GLS have been shown to be significantly reduced in
patient with CKD compared to controls (−13.3 ± 2.3% versus
−15.9 ± 2.9% and −14.2 ± 1.7% versus −15.9 ± 2.3%, resp.) [51].
Whilst it is possible tomeasure strain with CMR to assessMF
in the same way as with ECHO, no studies in patients with
renal disease that have reported CMR-derived strain values
have made direct assessments of MF and have tended to
report strain as a measure of subclinical systolic and diastolic
dysfunction rather than as a tool for assessment of MF.
2.1.1. Integrated Backscatter Analysis. Integrated backscat-
ter (IB) is a measure of the ultrasonic reflectivity of a
selected part of myocardium, usually the posterior wall. Cali-
brated integrated backscatter (cIB) uses an intrinsic material
such as pericardium (which appears brighter than normal
myocardium due to the higher content of fibrosis) or blood
(which appears darker) as a frame of reference to compare
the reflectivity of myocardium [39] (Figure 2).
Animal studies have demonstrated strong associations
between cIB and histologically confirmed levels of MF, with
higher IB values associated with the presence of fibrosis
[53, 54]. IB has also been correlated with levels of fibrosis in
patients with dilated cardiomyopathy [55], congestive heart
failure patients [56], and myocardial infarction/ischemic
heart disease [57, 58]. Naito et al. demonstrated that cIB
was higher in patients with dilated cardiomyopathy than in
healthy controls (46.9± 6.1 dB versus 42.0± 4.4 dB for septum
and 37.4 ± 6.5 dB versus 31.0 ± 5.0 dB for LV posterior wall,
𝑝 < 0.01) and that high cIB associated with increased fibrosis
in the biopsy specimen of heart tissue (𝑟 = 0.68, 𝑝 < 0.01 for
septum; 𝑟 = 0.71, 𝑝 < 0.01 for LV posterior wall) [55]. Picano
et al. studied 16 patients with congestive cardiac failure/
suspected cardiomyopathy who underwent LV biopsy and
ultrasonic myocardial tissue characterization and found a
significant correlation between percent connective tissue area
and percent-integrated backscatter index (𝑟 = 0.55, 𝑝 < 0.05)
[56]. However, the authors acknowledged that themyocardial
biopsywas not taken from the same area of interest imaged by
ultrasound. Not all studies have shown a positive relationship
between cIB and histological fibrosis content however. Prior
et al. assessed 40 patients undergoing coronary artery bypass
grafting and found that levels of fibrosis varied between
subjects from 0.7% to 4% and there was no significant
relationship between histological evidence of fibrosis on
biopsy and preoperative cIB echocardiogram [58].This study
suggested that cIB is less reliable for lower levels of fibrosis. So,
cIB may be able to characterize replacement fibrosis but not
more subtle diffuse processes. The observer variability of cIB
has been assessed in healthy, young subjects, with good intra-
observer (𝑟 = 0.92) and interobserver (𝑟 = 0.88) repro-
ducibility [59].
Studies that have used IB in HD patients are summarised
in Table 2 [60–62]. Salvetti et al. found that mean reflectivity
of IB was increased progressively from 48% in patients with
essential hypertension to 56% in patients with CKD, further
increasing to 62% in HD patients (𝑝 < 0.01 for all groups)
[60]. Although this was not correlated histologically against
levels of fibrosis, the authors speculated that increase in IB
reflectivity was due to LV collagen deposition, beginning
before the development of ESRD. Losi et al. also showed that
mean IB was greater in ESRD patients compared to controls
(45.2 ± 8.6 versus 36.8 ± 6.1%, 𝑝 = 0.025) and that IB
was an independent predictor of diastolic dysfunction (odds
ratio = 1.212; 𝑝 = 0.04) [61]. Furthermore, they performed
intraobserver variability of IBmeasurement in 10 consecutive
patients, finding variability to be 2%, with a repeatability
coefficient of 1.35. A nonrandomised study by Jin et al.
assessed the effect of incentre nocturnal HD (INHD) on cIB
measurements [62].They showed that cIB reduced in patients
on INHD compared to conventional HD. In addition to a
reduction in cIB at twelve months, patients who underwent
INHD had a significant reduction in LV mass index, leading
the authors to suggest that INHD had reduced levels of MF
in the INHD group.
These studies did not assess the correlation between cIB
and histological presence of fibrosis in patients with ESRD.
Whilst the inter- and intraobserver variability of cIB appear
to be good, test-retest reproducibility has not been established
and the correlation coefficients described between cIB and
histologically proven fibrosis in other disease states are not
consistent or as closely matched as necessary for an imaging
biomarker.
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Table 2: Integrated backscatter used to assess myocardial fibrosis in patients with ESRD: IB, integrated backscatter; HD, hemodialysis; CKD,
chronic kidney disease; INHD, incentre nocturnal hemodialysis.
Study Patient characteristics Results Limitations
Losi et al. [61]
Case-control study
with 25 ESRD
patients on HD
Mean (±standard deviation) IB
was greater in patients with
ESRD than in controls (45.2 ±
8.6 dB versus 36 ± 6.1 dB;
𝑝 = 0.025). A significant
determinant of diastolic
dysfunction as measured by
echocardiography was mean IB
with odds ratio of 1.212
(𝑝 = 0.04)
Small study as very
selective patient criteria for
inclusion
Salvetti et al. [60]
Case-control study
with matched 25 HD
patients, 25 patients
with
moderate-to-severe
CKD, 10 patients with
essential hypertension
with normal renal
function
Mean reflectivity of IB was
progressively increased from
48% in patients with essential
hypertension to 56% in patients
with CKD to 62% in HD patients
(𝑝 < 0.01)
The increase in IB reflectivity
indicates possible early increase
in LV collagen deposition,
beginning well before the
development of ESRD
No histological data from
biopsies to confirm fibrosis
Jin et al. [62]
Non-RCT with 58
ESRD patients on
conventional HD
matched with 32
INHD patients
At 12 months, mean (±standard
deviation) cIB decreased
significantly from −20.2 ± 3.7 dB
to −28.1 ± 4.0 dB (𝑝 < 0.01) in
INHD patients and cyclic
variations in IB increased in
INHD patients; INHD improved
echocardiogram markers for
myocardial fibrosis
Nonrandomised, small
study with short follow-up
time. No histological data
from biopsies available to
confirm fibrosis
2.1.2. Common Limitations of Echocardiography. There are
limitations to the use of echocardiography for the assessment
ofMF common to both STE and IB techniques.Measurement
of IB and STE by echocardiography is dependent on image
quality which varies depending on patient and operator
related factors. In the studies of patients with ESRDdescribed
above, between 4 and 16.9% of subjects had echocardio-
graphic data excluded due to poor image quality [42, 44, 61].
Strict standardization of methodology is required to reduce
the risk of significant intra- and interobserver variability [39,
72], and expertise is required to assure sufficient accuracy and
reproducibility of these techniques. Discrepancies between
intervendor software analyses mean that studies using differ-
ent softwaremaynot be directly comparable. Finally, echocar-
diography is inherently dependent on patient volume status
and over- or underestimating ejection fraction depending
on fluid status [73], a particular problem when dealing with
patients with ESRD prone to fluctuations in volume status
that undoubtedly affect the reproducibility of STE derived
strain values.
2.2. Cardiac Magnetic Resonance Imaging. CMR is the gold
standard in cardiac imaging, with excellent intra- and inter-
observer variability for assessment of LV volumes and mass
[74]. Several CMR techniques may be used to identify
myocardial fibrosis. In the general population late gadolin-
ium enhancement (CMR-LGE) using gadolinium based con-
trast agents (GBAs) is the techniquemost commonly used for
assessing replacement scar fibrosis—often following myocar-
dial infarction. Fibrotic areas show up as bright, due to
the increased volume of distribution of gadolinium and its
prolonged washout from fibrotic tissue [75, 76] (Figure 3).
Mark et al. used CMR-LGE to define the pathological cardiac
changes that occur in patients with ESRD [52]. They studied
134 patients with ESRD and performed CMR to assess for
LGE. Myocardial fibrosis was found in 28.4% of patients,
with two main patterns identified. Subendocardial LGE
representing prior myocardial infarction was seen in 14.2%
of patients and 14.2% of patients displayed diffuse LGE rep-
resenting regions of DMF. This latter diffuse LGE was asso-
ciated with greater LV mass compared to patients without
LGE. This is a sensitive and reproducible way of assessing
focalMF; however there are limitations in using LGE to assess
DMF due to the reliance of the technique on demonstrating
a difference between signal intensity of normal and fibrotic
myocardial tissue [77]. Extracellular volume (ECV) quan-
tification using pre- and postcontrast T1 mapping sequences
(see below) are alternative methods to demonstrate DMF but
are also reliant on the use of GBAs to measure the volume
of the extracellular space, reflecting interstitial disease and
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Figure 3: (a) Short-axis view of the left ventricle of hemodialysis patient demonstrating a diffuse area of gadolinium enhancement in the
inferior wall of the left ventricle (arrowed). Signal intensity of this area is 17.6 compared to the 6.9 for the LGE-negative area. (b) Short-axis
view of the left ventricle of another hemodialysis patient demonstrating a diffuse area of gadolinium enhancement in the lateral wall of the
left ventricle. Signal intensity of the area of late gadolinium enhancement is 32.0 compared to 8.4 for the LGE-negative area. This patient had
normal coronary arteries at angiography performed as transplant assessment. Image and legend are taken from [52].
characterizing myocardial tissue [78]. The advantage of this
technique over LGE is that it is able to directly quantify the
extent of ECM expansion [79].
Unfortunately, CMR-LGE andECVquantification are not
possible in patients with ESRD (or CKD 3–5) due to the risk
of Nephrogenic Systemic Fibrosis (NSF) fromGBAs [80–82].
As long as GBAs are considered unsafe for use in patients
with renal disease, alternative CMR imaging techniques
are required to assess myocardial fibrosis in this patient
population. Furthermore, given that CMR-LGE has limited
ability to define DMF [83], development of novel CMR
techniques that can quantify DMF is desirable regardless of
the safety profile of GBAs.
2.2.1. Native T1 Mapping. Native T1 mapping is a novel
noncontrast CMR technique that enhances tissue character-
ization with CMR. T1 relaxation time is dependent on the
molecular environment of water molecules within a given
tissue. Native T1 signal can be affected by a number of differ-
ent factors andT1mapping characterizes different tissue com-
positionswith great specificity [84].Myocardial oedema, pro-
tein deposition, and interstitial fibrosis will lengthen the T1
recovery time, whilst iron overload and fatty deposits will
shorten T1 time (Figure 4).
There are a number of different pulse sequences that can
be used to measure myocardial native T1 time, the modified
look-locker inversion (MOLLI) recovery sequence and the
shortened modified look-locker inversion (shMOLLI) recov-
ery sequence being two examples
Native T1mapping has been shown to be a useful imaging
biomarker in a number of disease states (Table 3). Bull et al.
studied 96 patients with severe aortic stenosis (AS) and age-
matched controls [63]. They found that T1 values (imaged at
1.5 Teslas) were significantly longer in those with AS than in
controls (T1 = 966 ± 41ms versus 939 ± 19ms, resp., 𝑝 <
0.001) and therewas significant correlation betweenT1 values
and histological fibrosis content (determined by collagen
volume fraction) from endomyocardial biopsy (𝑟 = 0.65,
𝑝 = 0.002) [63]. Similarly Karamitsos et al. compared native
T1 times (1.5 T) of patients with AL amyloidosis to those of
patients with AS with equivalent degrees of LVH and healthy
controls [64]. They found that T1 values were increased in
those with AL amyloidosis compared to patients with AS
and healthy controls (1140 ± 61ms versus 979 ± 51ms, 958 ±
20ms, both 𝑝 < 0.001). They identified that raised T1 values
in amyloidosis patients correlated with systolic and diastolic
dysfunction. There was no histological component to this
study however, and it is likely that myocardial amyloid pro-
tein deposition causes raised native T1 times in these patients.
Further work is needed to determine whether there is an
absolute native T1 time cut-off or identification of patterns
that differentiate amyloid fromMF.
2.2.2. T1 Mapping in Patients with ESRD. The potential
benefits of T1 mapping in patients with ESRD to define MF
are clear [85]. Currently only 3 studies have reported native
T1 values in ESRD patients (Table 4). All of these studies were
done on a 3-Tesla (3 T)MRI platform and all used theMOLLI
sequence to generate native T1 maps.
Rutherford et al. showed that native T1 times in 33 HD
patients were significantly higher than 28 age- and sex-
matched control subjects imaged at 3 T (1171 ± 27ms versus
1154 ± 32ms, 𝑝 = 0.025) [70]. The same study also demon-
strated that global native T1 values in HD patients correlated
with LV mass indices (𝑟 = 0.452, 𝑝 = 0.008) and that septal
T1 values correlate with predialysis highly sensitive Tro-
ponin-T (𝑟 = 0.397, 𝑝 = 0.027) [70].These findings were cor-
roborated with findings from our group in a study showing
native T1 time are significantly higher in 35 HD patients than
22 comorbidity matched controls (1269.5ms (1241.7–1289)
versus 1085.2ms (1066–1109.2, 𝑝 < 0.01). Furthermore we
found that native T1 times were significantly higher in the
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Table 3: T1 mapping in myocardial fibrosis caused by different conditions. AS, aortic stenosis; HCM, hypertrophic cardiomyopathy; DCM,
dilated cardiomyopathy; LGE, late gadolinium enhancement; LVH, left ventricular hypertrophy; STEMI, ST-elevation myocardial infarction;
NSTEMI, non-ST-elevation myocardial infarction; shMOLLI, shortened modified look-locker inversion; MOLLI, modified look-locker
inversion.
Condition Study Results Limitations
AS Bull et al. [63]
Significant correlation between T1 value
and histological degree of fibrosis
(collagen volume fractions) 𝑟 = 0.65,
𝑝 = 0.002
Due to age matching with
patients with AS, older
subjects were examined in
this study, which could
affect the T1 values
Amyloidosis Karamitsos et al. [64]
Significantly increased mean (±standard
deviation) myocardial T1 in patients with
AL amyloidosis compared to normal
subjects (1140 ± 61ms versus 958 ± 20ms:
𝑝 < 0.001). T1 mapping could detect
cardiac amyloidosis, even when it was
thought to be absent when assessed by
echocardiography criteria and standard
biomarkers
Results compared to
echocardiographic criteria
of myocardial amyloidosis
and not histological data
Hypertrophic
cardiomyopathy
and dilated
cardiomyopathy
Dass et al. [65]
Mean (±standard deviation) T1 relaxation
time per subject was significantly elevated
in both HCM and DCM in comparison to
controls (HCM 1209 ± 28ms, DCM 1225
± 42ms, control 1178 ± 13ms, 𝑝 < 0.05).
There was modest correlation between T1
mapping and fibrosis identified by LGE;
however T1 values were also increased in
segments without LGE suggesting
distinct pathologies being measured
Small sample size
Did not study extracellular
volume fractions and
therefore can only speculate
the mechanisms underlying
correlations between T1
values and impaired
myocardial function. Used
LGE to confirm fibrosis
rather than histological
analysis
Fabry disease Pica et al. [66]
Mean (±standard deviation) native T1 in
patients with Fabry disease with and
without LVH was lower compared to
healthy volunteers (853± 50ms and
904± 46ms, resp., versus 968± 32ms,
𝑝 < 0.0001). In patients without LVH,
reduced T1 is associated with ECHO
parameters of cardiac dysfunction
suggesting that a low T1 is detecting early
cardiac disease
Small single-centre study.
No comparison with biopsy
or cardiac magnetic
resonance spectroscopy for
measuring myocardial lipid
storage
Chronic
myocardial
infarction
Kali et al. [67]
Good agreement between LGE and T1
mapping measuring infarct size
(𝑅(2) = 0.93 in STEMI and 0.85 in
NSTEMI, 𝑝 < 0.05) demonstrating that
chronic myocardial infarction size,
location, and transmurality can be
reliably characterised by T1 mapping
Small sample size and a
single-centre study. Did not
acquire T2 maps to confirm
resolution of acute oedema
Iron overload Sado et al. [68]
Mean (±standard deviation) myocardial
T1 was lower in patients with iron
overload than in healthy volunteers
(836± 138ms versus 968± 32ms,
𝑝 < 0.0001). T1 reproducibility was also
shown to be significantly superior to T2
Significant interstudy and
intraobserver differences
between the T2 mapping
and either of the T1
mapping methods
(shMOLLI versus MOLLI)
Acute
myocarditis Ferreira et al. [69]
Using a threshold of T1> 990ms
(sensitivity 90%, specificity 88%), they
found that T1 mapping detected
significantly larger areas of myocardial
injury (32%) than T2-weighted and LGE
(11% and 5%, resp.) imaging in all patients
Differentiation of
myocardial areas affected
by acute oedema however
with no data on chronic
scarring/fibrosis
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Figure 4: (a) Short-axis midventricular native T1 map of a dialysis patient. Black arrows show areas of discretely increased signal intensity
likely to represent myocardial fibrosis. (b) Corresponding short-axis midventricular plain cardiac MRI cine image of the left ventricle of the
same dialysis patient. No tissue abnormality visible on plain MR imaging.
interventricular septum of HD patients, compared to non-
septal myocardium (1292.7ms (1258.9–1310.4) versus 1252.3
(1219.2–1269.6), 𝑝 = 0.002) a difference not present in control
patients. Significant correlations were also described between
GCS, GLS (measured with CMR), and native T1 values (𝑟 =
0.41, 𝑝 = 0.002, 𝑟 = 0.55, and 𝑝 < 0.001) [71]. These results
are consistent with a study by Edwards et al., which showed
significantly longer native T1 times in 129 patients with CKD
stages 2–4 (at 1.5 T) compared with age- and gender-matched
control subjects and patients with hypertension (986 ± 37ms
versus 955 ± 30ms versus 956 ± 31ms, 𝑝 < 0.05) [86]. The
study by Edwards et al. also showed a correlation between
native T1 time and GLS (𝑟 = 0.22, 𝑝 < 0.05). The interstudy
and interobserver reproducibility of native T1 mapping also
appear to be extremely good with coefficients of variation
of 0.7% and 0.3%, respectively [87]. Furthermore, early data
suggests that changes in fluid status do not affect native T1
signal in HD patients. Our study on the interstudy repro-
ducibility of native T1 mapping showed that whilst changes
in weight between scans correlated well with changes in left
ventricular end-diastolic volume due to change in volume
status and loading, there was no relationship between either
change in weight or change in left ventricular end-diastolic
volume between scans and change in native T1 time [87].
Wang et al. reported a study of HD patients that whilst
native T1 times at 3 T were significantly higher than the
established normal range [88] (1273.4 ± 41.7ms), they were
not significantly higher compared to the control group (1253.1
± 71.6ms) [89]. The control values quoted by Wang et al. are
significantly above the normal ranges for native T1 at 3 T pre-
viously published, with no explanation given as to why
this might be. The same study did, however, report that
native T1-rho values were significantly higher in HD patients
than in healthy controls (52.2± 4.0ms versus 49.4± 2.6ms,
𝑝 = 0.001). They also showed the reproducibility of T1-rho
mapping was very good, with interobserver intraclass corre-
lation coefficient (ICC) of 0.966, intraobserver ICC of 0.937
for two readers, and test-retest interstudy ICC of 0.836 for the
volunteer subjects.
Studies are needed that correlate native T1 mapping
with histological specimens from patients with ESRD to
demonstrate unequivocally that increased T1 values are due
to myocardial fibrosis and not myocardial oedema from fluid
overload or any other disease processes.
2.2.3. Limitations of CMR. Whilst CMR is regarded as the
gold standard for noninvasive assessment of cardiac structure
and function, it is not without limitations. CMR is costly
and not widely available and considerable skill is required for
image acquisition and analysis. Furthermore postprocessing
and analysis of scans can be time-consuming and may
require bespoke software applications that are expensive.
Additionally there will always be a subset of patients who
are unable to undergo CMR scanning due to claustrophobia,
metallic implants, or inability to lie flat.
3. Conclusions
In 2011, Sado et al. reviewed the imaging techniques to
define DMF, including the modalities we have discussed,
and laid out a framework for technique development [90].
They concluded that no imaging modality fulfils all the
criteria required to confidently define MF and the evidence
we have discussed supports this view. To be considered a
reliable imaging biomarker of MF, techniques should do
the following: be proven to compare closely with histo-
logical specimens from human subjects; detect changes in
established disease states compared with controls; correlate
with cardiac markers of MF (e.g., diastolic function, LVH);
correlate with blood biomarkers of MF; be able to track
changes over time; and be standardized in the way they
are carried out (intervendor/intercentre) and changes in the
biomarker should track changes in the disease after treat-
ment.
Echocardiography has limited accuracy and reproducibil-
ity in defining geometric parameters and indices of systolic
and diastolic function.This is especially true for HD patients
who are subject to changes in cardiac filling from fluid status;
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Table 4: Studies that have used myocardial native T1 mapping in hemodialysis patients. 3 T, 3-Tesla; MOLLI, modified look-locker inversion;
HD, hemodialysis; ms, millisecond; GCS, global circumferential strain; GLS, global longitudinal strain.
Study Imaging Platform and T1mapping sequence Patient characteristics Results Limitations
Rutherford et al. [70] 3 T platformMOLLI sequence
33 incident HD patients, 28
age- and sex-matched
healthy controls
Mean native T1 values
significantly higher in HD
patients compared to
controls (1171 ± 27ms
versus 1154 ± 32ms,
𝑝 = 0.025). Native T1
correlated LV mass index
(𝑟 = 0.452, 𝑝 = 0.008) and
septal T1 values correlated
with predialysis highly
sensitive Troponin-T
(𝑟 = 0.397, 𝑝 = 0.027)
No tissue correlation
Healthy control patients
Graham-Brown et al.
[71]
3 T platform
MOLLI sequence
35 HD patients,
22 comorbid matched
controls
Median (interquartile
range) native T1 times were
significantly higher in HD
patients compared to
controls (1269.51ms
(1241.72–1289.01) versus
1085.2ms (1066–1109.2,
𝑝 < 0.01). Native T1 times
were significantly higher in
the interventricular septum
of HD patients, compared
to nonseptal myocardium
(1292.7ms (1258.9–1310.4)
versus 1252.3
(1219.2–1269.6), 𝑝 = 0.002).
Significant correlations
between GCS, GLS, and
native T1 values (𝑟 = 0.41,
𝑝 = 0.002, 𝑟 = 0.55, and
𝑝 < 0.001)
No tissue correlation No
circulating biomarkers of
cardiac disease or fibrosis
Wang et al. 3 T platformMOLLI sequence
32 HD patients
35 healthy volunteers
Mean (±standard
deviation) native T1 values
significantly above the
normal range for imaging
at 3 T (1273.4 ± 41.7ms),
but not significantly higher
than control patients within
this study (1253.1 ± 71.6ms)
𝑝 = 0.157
Control group native T1
values significantly above
the normal range. No tissue
correlation
LV mass and cavity size may be overestimated in up to 50%
of dialysis patients [91]. Whilst STE and IB correlate with
MF in some diseases, they have not been validated against
tissue in HD patients. Furthermore the reproducibility of
these techniques appears to lack robustness.
Although modern, more stable, macrocyclic GBAs are
now available, which are potentially less toxic [92], it is
unlikely they will be approved for use in patients with ESRD.
Moreover, as CMR-LGE cannot accurately define DMF
[83], development of alternative CMR techniques is needed.
Although it is in the early stage of development in patients
with ESRD, native T1 mapping shows promise. It correlates
well with histology in patients with aortic stenosis [63], is
significantly raised in patients with ESRD compared to con-
trols [70, 71], correlates significantly with measures of strain
assessed by CMR [71], correlates with circulating markers
of cardiac disease [70], and has excellent interobserver and
interstudy reproducibility [87]. Further studies are required
to correlate native T1 mapping with levels of MF in patients
with ESRD and assess the effect of fluid status on T1 values
to ensure cardiac oedema is not contributing to the reported
raised T1 values. Further data are needed to determine
whether T1 is an independent predictor of CV events in
patients with ESRD [8].
Whilst imaging biomarkers ofMF are attractivemeasures
for future interventional RCTs, we first needmore robust and
BioMed Research International 11
complete data on the relationship between the markers and
their relationship to hard outcomes.
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